Skip to main content
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1995 Jun 1;181(6):2229–2235. doi: 10.1084/jem.181.6.2229

Identification of class II major histocompatibility complex and T cell receptor binding sites in the superantigen toxic shock syndrome toxin 1

PMCID: PMC2192066  PMID: 7760008

Abstract

Superantigens, in association with class II major histocompatibility complex (MHC) molecules, activate T cells bearing particular beta chain variable domains of the T cell receptor (TCR). Unlike conventional peptide antigens, superantigens bind as intact proteins to TCR and MHC molecules outside their peptide binding sites. To characterize these interactions at the molecular level, random point mutations were generated in the gene encoding toxic shock syndrome toxin 1, a bacterial superantigen associated with toxic shock syndrome. Functionally impaired mutants were identified based on their lack of murine and human T cell stimulatory activities, and experiments analyzing binding to human histocompatibility leukocyte antigen-DR molecules differentiated residues involved in MHC from TCR binding. The results showed that the great majority of mutations are clustered in two distinct regions of the toxic shock syndrome toxin 1 molecule. The class II MHC binding site is located in the hydrophobic region of the NH2-terminal domain, and the TCR binding site is primarily in the major central groove of the COOH-terminal domain. These studies provide insight into the interactions necessary for superantigen-mediated disease in humans.

Full Text

The Full Text of this article is available as a PDF (698.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe J., Kotzin B. L., Meissner C., Melish M. E., Takahashi M., Fulton D., Romagne F., Malissen B., Leung D. Y. Characterization of T cell repertoire changes in acute Kawasaki disease. J Exp Med. 1993 Mar 1;177(3):791–796. doi: 10.1084/jem.177.3.791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Acharya K. R., Passalacqua E. F., Jones E. Y., Harlos K., Stuart D. I., Brehm R. D., Tranter H. S. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. Nature. 1994 Jan 6;367(6458):94–97. doi: 10.1038/367094a0. [DOI] [PubMed] [Google Scholar]
  3. Aiyar A., Leis J. Modification of the megaprimer method of PCR mutagenesis: improved amplification of the final product. Biotechniques. 1993 Mar;14(3):366–369. [PubMed] [Google Scholar]
  4. Blanco L., Choi E. M., Connolly K., Thompson M. R., Bonventre P. F. Mutants of staphylococcal toxic shock syndrome toxin 1: mitogenicity and recognition by a neutralizing monoclonal antibody. Infect Immun. 1990 Sep;58(9):3020–3028. doi: 10.1128/iai.58.9.3020-3028.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Blomster-Hautamaa D. A., Kreiswirth B. N., Kornblum J. S., Novick R. P., Schlievert P. M. The nucleotide and partial amino acid sequence of toxic shock syndrome toxin-1. J Biol Chem. 1986 Nov 25;261(33):15783–15786. [PubMed] [Google Scholar]
  6. Bonventre P. F., Heeg H., Cullen C., Lian C. J. Toxicity of recombinant toxic shock syndrome toxin 1 and mutant toxins produced by Staphylococcus aureus in a rabbit infection model of toxic shock syndrome. Infect Immun. 1993 Mar;61(3):793–799. doi: 10.1128/iai.61.3.793-799.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Choi Y. W., Kotzin B., Herron L., Callahan J., Marrack P., Kappler J. Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc Natl Acad Sci U S A. 1989 Nov;86(22):8941–8945. doi: 10.1073/pnas.86.22.8941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Choi Y., Lafferty J. A., Clements J. R., Todd J. K., Gelfand E. W., Kappler J., Marrack P., Kotzin B. L. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med. 1990 Sep 1;172(3):981–984. doi: 10.1084/jem.172.3.981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Clarke G. R., Reyburn H., Lancaster F. C., Boylston A. W. Bimodal distribution of V beta 2+CD4+ T cells in human peripheral blood. Eur J Immunol. 1994 Apr;24(4):837–842. doi: 10.1002/eji.1830240410. [DOI] [PubMed] [Google Scholar]
  10. Conrad B., Weidmann E., Trucco G., Rudert W. A., Behboo R., Ricordi C., Rodriquez-Rilo H., Finegold D., Trucco M. Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature. 1994 Sep 22;371(6495):351–355. doi: 10.1038/371351a0. [DOI] [PubMed] [Google Scholar]
  11. Dyer D. W., Iandolo J. J. Rapid isolation of DNA from Staphylococcus aureus. Appl Environ Microbiol. 1983 Jul;46(1):283–285. doi: 10.1128/aem.46.1.283-285.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Howell M. D., Diveley J. P., Lundeen K. A., Esty A., Winters S. T., Carlo D. J., Brostoff S. W. Limited T-cell receptor beta-chain heterogeneity among interleukin 2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10921–10925. doi: 10.1073/pnas.88.23.10921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jardetzky T. S., Brown J. H., Gorga J. C., Stern L. J., Urban R. G., Chi Y. I., Stauffacher C., Strominger J. L., Wiley D. C. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature. 1994 Apr 21;368(6473):711–718. doi: 10.1038/368711a0. [DOI] [PubMed] [Google Scholar]
  14. Kappler J. W., Herman A., Clements J., Marrack P. Mutations defining functional regions of the superantigen staphylococcal enterotoxin B. J Exp Med. 1992 Feb 1;175(2):387–396. doi: 10.1084/jem.175.2.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Karp D. R., Teletski C. L., Scholl P., Geha R., Long E. O. The alpha 1 domain of the HLA-DR molecule is essential for high-affinity binding of the toxic shock syndrome toxin-1. Nature. 1990 Aug 2;346(6283):474–476. doi: 10.1038/346474a0. [DOI] [PubMed] [Google Scholar]
  16. Kotzin B. L., Leung D. Y., Kappler J., Marrack P. Superantigens and their potential role in human disease. Adv Immunol. 1993;54:99–166. doi: 10.1016/s0065-2776(08)60534-9. [DOI] [PubMed] [Google Scholar]
  17. Lee P. K., Kreiswirth B. N., Deringer J. R., Projan S. J., Eisner W., Smith B. L., Carlson E., Novick R. P., Schlievert P. M. Nucleotide sequences and biologic properties of toxic shock syndrome toxin 1 from ovine- and bovine-associated Staphylococcus aureus. J Infect Dis. 1992 Jun;165(6):1056–1063. doi: 10.1093/infdis/165.6.1056. [DOI] [PubMed] [Google Scholar]
  18. Leung D. Y., Meissner H. C., Fulton D. R., Murray D. L., Kotzin B. L., Schlievert P. M. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet. 1993 Dec 4;342(8884):1385–1388. doi: 10.1016/0140-6736(93)92752-f. [DOI] [PubMed] [Google Scholar]
  19. Marrack P., Kappler J. The staphylococcal enterotoxins and their relatives. Science. 1990 May 11;248(4956):705–711. doi: 10.1126/science.2185544. [DOI] [PubMed] [Google Scholar]
  20. Murray D. L., Prasad G. S., Earhart C. A., Leonard B. A., Kreiswirth B. N., Novick R. P., Ohlendorf D. H., Schlievert P. M. Immunobiologic and biochemical properties of mutants of toxic shock syndrome toxin-1. J Immunol. 1994 Jan 1;152(1):87–95. [PubMed] [Google Scholar]
  21. Paliard X., West S. G., Lafferty J. A., Clements J. R., Kappler J. W., Marrack P., Kotzin B. L. Evidence for the effects of a superantigen in rheumatoid arthritis. Science. 1991 Jul 19;253(5017):325–329. doi: 10.1126/science.1857971. [DOI] [PubMed] [Google Scholar]
  22. Panina-Bordignon P., Fu X. T., Lanzavecchia A., Karr R. W. Identification of HLA-DR alpha chain residues critical for binding of the toxic shock syndrome toxin superantigen. J Exp Med. 1992 Dec 1;176(6):1779–1784. doi: 10.1084/jem.176.6.1779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pietra B. A., De Inocencio J., Giannini E. H., Hirsch R. TCR V beta family repertoire and T cell activation markers in Kawasaki disease. J Immunol. 1994 Aug 15;153(4):1881–1888. [PubMed] [Google Scholar]
  24. Prasad G. S., Earhart C. A., Murray D. L., Novick R. P., Schlievert P. M., Ohlendorf D. H. Structure of toxic shock syndrome toxin 1. Biochemistry. 1993 Dec 21;32(50):13761–13766. doi: 10.1021/bi00213a001. [DOI] [PubMed] [Google Scholar]
  25. Ringquist S., Shinedling S., Barrick D., Green L., Binkley J., Stormo G. D., Gold L. Translation initiation in Escherichia coli: sequences within the ribosome-binding site. Mol Microbiol. 1992 May;6(9):1219–1229. doi: 10.1111/j.1365-2958.1992.tb01561.x. [DOI] [PubMed] [Google Scholar]
  26. Sarkar G., Sommer S. S. Double-stranded DNA segments can efficiently prime the amplification of human genomic DNA. Nucleic Acids Res. 1992 Sep 25;20(18):4937–4938. doi: 10.1093/nar/20.18.4937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Scholl P., Diez A., Mourad W., Parsonnet J., Geha R. S., Chatila T. Toxic shock syndrome toxin 1 binds to major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4210–4214. doi: 10.1073/pnas.86.11.4210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Swaminathan S., Furey W., Pletcher J., Sax M. Crystal structure of staphylococcal enterotoxin B, a superantigen. Nature. 1992 Oct 29;359(6398):801–806. doi: 10.1038/359801a0. [DOI] [PubMed] [Google Scholar]
  29. Thibodeau J., Labrecque N., Denis F., Huber B. T., Sékaly R. P. Binding sites for bacterial and endogenous retroviral superantigens can be dissociated on major histocompatibility complex class II molecules. J Exp Med. 1994 Mar 1;179(3):1029–1034. doi: 10.1084/jem.179.3.1029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Todd J. K. Toxic shock syndrome. Clin Microbiol Rev. 1988 Oct;1(4):432–446. doi: 10.1128/cmr.1.4.432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Todd J., Fishaut M., Kapral F., Welch T. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet. 1978 Nov 25;2(8100):1116–1118. doi: 10.1016/s0140-6736(78)92274-2. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES